Date: February 9, 2016 To NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E}, MUMBAI -400 051 Company Code No. AUROPHARMA & AUROBINDO To - | BSE LIMITED Phiroz. Jeejeebhoy Towers, 25" fioor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 Dear Sirs, SUB: Press Release - Reg Please find enclosed herewith a copy of Press Release issued by the Company, This is for your information and record Thanking you, Yours faithuly, For AUROBINDO PHARMA LIMITED ‘AMOHAN RAMI REDDY Vice President (Legal) & Company Secretary AUROBINDO PHARMA LIMITED (GIN :L24238T61986PLC015190) PAN No, AABCA7366H ‘Corp off: The Water Mark Building Pot No, Survey No.8, Hi-tech City, Kondapur, Hyderabad ~ 600 084 T.S., NDIA Tel: +91 40 6672 5000/1200 Fax: +81 40.6707 4059 ‘Regd. Off. : Pot No. 2, Maitrvihar pet, Hyderabad -500 038 TS. INDIA Tol: +81 40 2873 6370 Fan: «81 40 2974 7340, Ema: inoue com www. aurobindo.conAUROBINDO NEWS RELEASE 9 February 2016, Hyderabad, India Q3 FY15-16 Unaudited Ean ae Consolidated Net Operating Income" | 3,166.2 EBITDA before Forex 6122 EBITDA % _ 19.3 BT before Forex 58.9 "AT (after minority interest) 3844 [382 451.8 | 184 "Wet of excise duty Key Consolidated Financial Highlights for Q3 FY1S-16 (Unaudited) on YoY bas! + Total Operating Income up by 10% to INR 3,496 Cr vs INR 3,166 Cr + Operating Profit (EBIDTA) before Forex up 34.4% to INR 823 Cr vs INR 612 Cr, EBITDA margin at 23.5% + PBT before Forex up by 27% to INR 708 Cr vs INR 559 Cr + PAT after minority interest up by 40% to INR §35 Cr vs INR 384 Cr * Basic & Diluted EPS is INR 9.16 per share ‘+ Formulation Sales up by 12% to INR 2,837 Cr vs INR 2,530 Cr + API Sales registered 3% growth at INR 695 Cr vs INR 674 Cr + Formulations business constitute 80.3% (79.0%) and API 19.7% (21.0%) of gross sales * Interim Dividend @ 70% i.e, INR 0.70 per equity share of INR 1/- has been approved by the Board for the FY15-16 Commenting on the Company's performance, Mr, N. Govindarajan, Managing Director of the company sal We witnessed good growth on the back of new launches during the quarter. With focus on market penetration, ‘new product introductions including specialty segment and complex product R&D, we look forward to maintain the growth momentum. Formulations USA 15706 Europe 778.6 ROW ~ 162.2 ARV [305.4 Total Formulations 2,836.9 ‘Active Pharmaceuticals Ingredients Betalactum 449.3 Non Betalactum __| 245.9 Total API__ 695.2 Dossier Income Giand Total (n AUROBINDO PHARMA LIMITED (CIN :L2a29TG1986PLCO15190) PAN No. AABCA7366H op ots The Water Mak Buin, lt M1, Survey Mo tech Cy Kons, Hydrated ~ 00 84 TS INDIA Tal: +2 406872 8000/1200 Fav: «81406707 ose Aegd OF Po to. 2, May, Amel, Hyerabad S00 098 1, IA Tel: +91 402373 6970 Fx: +810 207 7940, Ema isu obinde.comAUROBINDO The formulations business witnessed YoY growth of 12% during the quarter primarily on account of higher growth in US and ROW market. The Europe sales decline by 9.6% YoY in INR primarily due to the currency impact a Euro depreciated by 6.5% during the quarter against corresponding quarter last yeer. ‘The Active Pharmaceuticals Ingredients business registered a growth of 3.1% during the quarter on a YoY basis. ‘The company sells API to domestic as well as the global market. During the quarter, the international sales stood at INR 3,114 Cr and the domestic sales were at INR 418 Cr representing 88% and 12% respectively. Global Requlatory Filing During the quarter, the company received approvals for 18 ANDAs including four tentative approvals. The total approvals for 9 Niths FY15-16 stands at 36 including 5 tentative approval eres) ON EYIESS ae "ANDAs (including flings made from Aurobindo USA) 5 387 DMFS (including filings made from AuroNext and e ay ‘AuroPeptide) Formulations Dossiers in other key advanced markeis | (incl, Multiple registrations into Europe. South Africa 104 2,592 and Canada) a ‘API DMFICOS flings in other key regulated markets {incl Multiple registrations) = oo Following approvals in USA (228 cumulative approvals including 30 tentative" by USFDA) were received during the quarter ended 31% Dec 2015: “Tentative approvals include 21 ANDAs approved under PEPFAR, not for commercialization in the US market usa Final Approvals 4. Aripiprazole Tab (Gx Abiliy®) 2/5/10/15/20'80mg ons 2, Memantine Hydrochloride Tab (Gx Namenda®) 5/10mg CNS 3. Tramadol Hydrochloride Extended-Release Tab (Gx Utrem®) 100/200/300 mg Controlled Substances 4. Sildenafil Citrate Tab (Gx Revatio®) 20mg cvs 5. Risedronate Sodium Tab (Gx Actonel@) 5/30/35 mg Others 6. Dexamethasone Sodium Phosphate Inj4 mg/ml (1/5/30 mL} Others 7. Epiifbatise Inj (Gx Integrin) 20 mg/10 mL, 75 mg/100 mL, and 200 mg/100 mL single-use vials cvs 8. Levonorgestrel Tab (OTC) (Gx Pian B One-Step) 1-5mq Others 8. Loperamide Hydrochioride Tab (Gx Imodium®) 2mg Gastroenterological 10, Methyiprednisolone Sodium Succinate for In (Gx Solu-Medrol®) 40/125/500maMial and 2 gramsivial Others 11, Olopatadine Hycrochioride Ophthalmic Solution (Gx Patanol@) 0.1% Opninalmics 12, Famotidine Tab (Gx Pepeid®) 20740mg Gastroenterological Tentative Approvals 1. Tadalafil Tab (Gx Adcirca®) 20mg cvs 2. Pelonosetron Hydrochloride Inj (Gx Aloxt®) 0.26 mg/S mL (0.05 mgmL) _ Gastroenterological 3. Bivalrudin for ny (Gx Angiomax®) 250 mglvial ovs 4. Esomeprazole Magnesium Delayed-Release Cap (Gx Nexium®) 20/40mg_ Gastroenterological AUROBINDO PHARMA LIMITED (CIN :124239TG1986PLC015190) PAN No. AABCA7366H Crp: Te Wat Mark Bug, Pt. Survey No itech Ci, andr, Hyerabd 500084, OIA Tel: +81 4068725000 200 Fan: +91 $0 67074058 Reg. Ff. Pat Ne, 2, Minar, Anenp, Hyderabad £00038 TS, INDI Tel: +91 4.237360 fa: 9140274728, Ea ile@atingacomf& AUROBINDO ‘About Aurobindo Pharma Limited: ‘Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: AREN.NS, Bloomberg: ARBP:IN) headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilties are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA, The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an ‘outstanding R&D set-up. The Company is marketing these products globally in over 150 countries, For further information, please contact: Investor Relations Deepika Gupta Padhi Phone’ 040-66725401 / 66725000 Mobile: +91 98486 67906 Email it@aurobindo.com Disclaimer: This press release contain statements that may constitute "forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments, ‘and economic performance. While these forward looking statements represent our judgment and future ‘expectations conceming the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations, The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information. AUROBINDO PHARMA LIMITED {CIN :L24239761986PL.C015190) PAN No, AABCA7S66H orp of: The Water Mark Bidin. Pt. Surey Ho Hitch Cy, Kado, yeah ~S00 084. INDIA Tel: «9140 85725000/ 1200 Fax: «914067074058 eg CPt Wo. 2, Mati, ene, dead £00038 TS, NDIA Tel: +81 4028796370 Fav: «91402978 730 Elion aurabindo.com& AUROBINDO AUROBINDO PHARMA LRATED. (Gn tzsoreronen.coss390) Readofice: lot No.3, Mattar, ner, yer 50005, no Tl 491 0402736870; ax 1944079747300, manta com tines) TETEHGENTOP GONSOUOATEO UNAUDITED RESUS FORTHE QUARTET & Ninf ONT ENOWD SUAEIOTS consoled Tisenoaiien ine meen | Youre e Particle SeeAoIs| soos avis EDTA] Baszamis [aa ore| ShonaoIs ‘Unavaited] Unavsited | Unsucted | Unaudited | Uneusted | Audited 1fincome rom operations {a} Net sales/income team operation (Net of excise dy) saaa08| 323011] 314255] 997502] sas,s25| 3,204,223 (01 ote operating income 632} 5336] 2370) yaaa] sus] 7.729 [rotat income trom operations (net) 349550] 333,347] si66i6| 010933] aosers| 3.212050 2expenses {2} Cost of material consumed saaas7|_ 11506] 113,129] 59288] aoo.016] 12201 {b) Purchase of stocksintade s3aza|as.213]tosaxs| 137570] 47.227 {Changes in inventories of tsshod goods, verkin- progress | (6290) (2427) @.675)] aaa) 3aain] (32: and stockintrade (c) Employee benefits expense aoaoz] 37592] sari] 115202] o2.0e 120,26 (6) Depreciation and ameteation expanse 3947] 9277] 6726] 83s) zara) azz6r (0 omer expences nay] ni206] 73261] sass: a7s'g08 rota! expenses zr7as6| 265065] 262.25] 10,703] 729,886 | ee052 sfprote/ (toss) fom: raasa| 65282] saaor| 206,290] 265.959} 223,101, costs, foreign exchange (gsin|/loss and exceptional tems (1-2) Jotner income esr] ates} ssa} azon] 7402] 76 [Prot (Los) from ordinary activites before finance costs, loreign exchange (gan loss and exceptional items (28) rao | 65.408 2ossa| a7ssei] 221477 nance costs rfer nate 4) 2a70| 2407| 2269] 6762) ea] sas foreign exchange (San/toss (refer note 4) (1253) 5.790] 2020) 73085] sas] 5.380) ‘[Prof/{Lss) rom ordinary activites after finance costs but lvetore exceptional ems (66-7) rages} x21] sara] assasr| aeian0] 26,76 sfescoptiona item 5 : 10)Profi /(Loss) rom ordinary activities before tax 8-9) rosa] si2s1] saya] assay] aerai0| ase 706 11) Tox expense/(eeat) as99] 16220] as6sa| zara] 24.320 60 sz}Net Prot Los) for the period (20-12) s3aes| 05,001 saxe6s| 136790] 357.126 43}Minonty nerest eo} ta] (aso) eos] asa 1alNet Profit/(Loss) after taxes and minorty Interest (22-83) sass] 5,176] sess) aengas| azase| —a57,577 43|poicsup Equity Shave Capital face value Re. 3 per share) sea] seo] 2o15| sao] as] 220 4e|Reseres excluding Revaluation Reserve 17}comings per share of Re./- each not annualised a) basic vas] 774] 660] 2as0] zon} arc i ovutes sas} 773] ssa] 242s] 2008] 9700 AUROBINDO PHARMA LIMITED (CIN -L24299TG1986PLC015190) PAN No. AABCA7368H pl: Te Wat ark ug, Pot Wo. Survey No Hee iy andap, Hyerabad~ 500084 OIA Tel; +81 40867200) 200 Far; «91 40 6707459 Rag. Ff: Ne 2, Mana, Asmar, Heat 500098 TS, OA Tel 91402879670 Fac: 840274724, Ena feta. www. aurobinds.com& AUROBINDO 1 The above consolidated unaudited financil results 9s reviewed by the Aust Committee have been approved by the Board of Directors ati raetng eld on Fon 9, 2016, 2 The conslited financial results have been prepared in accordance with AS -21 on “Consolidated Financial Statement! and AS-27* Financ Reporting of Interests inJolot Ventures" and Inelude financial rasulte ofall Subsiiris anda Jont Venture 3 The Company's operations fll within a single primary busines sagment vi. Pharmaceutics! Products 4 Foreign exchange (gain/oss for stand alone Includes exchange hference of Rs.2,068 lakhs, Re.7,296 lakhs, Rs.4635 las, for tree months fended December 31, 2015, September 30, 2015, and December 1, 2018 respectively and Re 15,884 lathe, Re 12.381 lakhs forthe nine months fended Oacember, 2015 and December, 2014 respectively and f.756 lk for the year ended March 34, 2015 arising ftom Foreign currency borowngs tothe extent that they are regarsed 35 an adjustment ofnance costa per par Ae) of “AS 16" on Borowing cost, '5 The Board of Directors at thelr meting held on September 12, 2013 decided to wansferit Injectable unit of the Company on a going concern bass comprising assets and lables petining tothe said unt Its wholly owned subsciry Curepr Parenterals Limited wie. Aan 3, 2014 The] some ie subject to recuse consent, approval or permission of the statutory or regulatory auhorties, Pending such approvals, no effect of ths] ‘scheme Fas been given inthe above rests 6 During the previous year, on December 4, 2014, Company's USA subsidary Aurobindo Patra USA In. has acauired Natal LLC, USA. The above Consolidated resus forthe quarter and nine months ended Oacemeer 3, 2025 and for the year ended March 31,2015 includes financial result of operations of Natrol LLC, USA flom December &, 2014, The comesponding figures ofthe varer and nine month ended December 31,2034 are| ot compatatie 7 The Company only 22, 2015, had allots 291,982,275 equty shares of Re.1/- each tothe shareholders of the Company as Bonus shares in the joof 18, Consequent 10 the aforesaid allotmort, the paid up equity share capital ofthe Company had increase rom 291,982,275 equity shores ff Rea/: each to $83,960,550 Equity Shares of Re.t/- each. The esmings per share has been agjusted for bans issue for previous perio presented in accordance with Acounting Standard 2, Eating per shar, {8 During the quarter APL Holdings (Jersey) Limited, 2 subsidary and APL IP Company Limited, @stepdown subsidiary of the Company have bee guided Actas Devischand Gib & Co K, a step down subssary ofthe Company wa ranted as Puren Pharma GmbH & Co KG 9.01 19th January, 2016 the Company has made allotment of 855,000 equity shares of Re.1/- each to the emoloyees ender Emoyee Stak Option Plan 2006, Consequent othe allotment the paid up share eapita ofthe Company Hes Ineessed to 584,819,580 equ shares of Re 2/- ech 10 The Board hos approved third interim dividend @70% Le. Rs.0.70 er equty shave of R.2/ forthe year 2015-16. Tis isin addition to interim} vidend © 50% and 60% on equity share capital of Company le. Rs. 0.50 and Rs. 0.60 per share pald in September, 2015 and November, 2015] respectwey fr the year 2015-16 11 Previous period figures have boon agrouped/rearanged wherever consisered necessary to conform tothe current petod presentation, By Order of the Board Pte: Hyderabad NGouindarajan bate Fetrary9, 2016 eewaurobindo.com Managing Director AUROBINDO PHARMA LIMITED (CIN -L.2423976 1986018190) PAN No, AABCA7366H Carat Te tr Mat Balog, Pt. Say Ne tech Gy, Kal, ya 5008S, MOM Te: «814087250020 ar: 140870408 Agi. Pa. 2 Mi, ea, dee 00 08 TS, DA Tal: 814298 8570 Fa: 140257478, cen www.aurobindo.com